Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Ulrich Kronthaler"'
Autor:
Ulrich Kronthaler, Thomas Stangler, Martin Fink, Matthias Hofmann, Anastassia Papandrikopoulou, Ines Meyer, Jan Marinus Visser, Vera Koppenburg, Antonio da Silva
Publikováno v:
Leukemia & Lymphoma
Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here we report the preclinical development of the proposed biosimilar rituximab (GP2013). Post-translational modifications and bioactiv
Autor:
Christoph Kleinschnitz, Guido Stoll, Ulrich Kronthaler, Ina Hagedorn, Gerhard Dickneite, Irina Pleines, Stefan Schmidbauer, Bernhard Nieswandt
Publikováno v:
Circulation. 121:1510-1517
Background— Blood coagulation is a tightly regulated process of sequentially activated serine proteases culminating in fibrin formation, which is critical for limiting posttraumatic blood loss but also may contribute to acute thrombotic diseases, m
Publikováno v:
Thrombosis and Haemostasis. 102:634-644
SummaryHaemophilia B is a X-chromosome linked disease characterised by a deficiency of functionally active coagulation Factor IX (FIX). Patients with severe haemophilia B at risk of recurrent bleeding are treated approximately twice a week in a proph
Autor:
Wiegand Lang, Stefan Schulte, Thomas Weimer, Ulrich Kronthaler, Uwe Liebing, Wilfried Wormsbächer
Publikováno v:
Thrombosis and Haemostasis. 99:659-667
SummaryFor the treatment of haemophilia patients with inhibitors, recombinant factor VIIa (rFVIIa) is available as a therapeutic option to control bleeding episodes with a good balance of safety and efficacy. However, the short in-vivo half-life of a
Autor:
Cornelius Fritsch, Hans-Peter Hofmann, Ulrich Kronthaler, Andreas Seidl, Antonio da Silva, Otmar Hainzl
Publikováno v:
American Journal of Gastroenterology. 111:S284
Publikováno v:
Annals of the Rheumatic Diseases. 73:943.2-943
Background TNFα inhibitors are highly effective drugs for the treatment of inflammatory disorders such as rheumatoid arthritis. Biosimilars are approved biologics with comparable quality, safety and efficacy to a reference product, which has lost ex
Autor:
Jan Marinus Visser, Thomas Stangler, Ulrich Kronthaler, Timo Schneiderer, Ines Meyer, Antonio da Silva, Cornelius Fritsch
Publikováno v:
Journal of Clinical Oncology. 31:3075-3075
3075 Background: Development of a biosimilar involves extensive characterization of the originator product and a target-directed iterative development process ensuring comparability to the originator with similar clinical efficacy, safety and quality
Autor:
Antonio da Silva, Thomas Stangler, Anastassia Papandrikopoulou, Ulrich Kronthaler, Jan Marinus Visser, Ines Meyer
Publikováno v:
Blood. 120:4867-4867
Abstract 4867 Background: Biosimilars are biologics approved by highly-regulated markets to be similar to existing agents that aim to offer more affordable treatment, thereby increasing patient access. Development of a biosimilar involves extensive c
Publikováno v:
Blood. 112:4523-4523
Introduction: Appropriate correction of hemostasis in VWD is essential not only to stop acute perioperative bleeding, but also to promote postoperative wound healing. In order to prevent a drop of the VWF plasma level below the hemostatically necessa
Autor:
Ulrich Kronthaler, Thomas Weimer, Uwe Liebing, Albrecht Groener, Stefan Schulte, Wilfried Wormsbaecher, Wiegand Lang
Publikováno v:
Blood. 110:3142-3142
For the treatment of hemophilia patients with inhibitors, recombinant Factor VIIa (rFVIIa) is available as a therapeutic option to control bleeding episodes with a good balance of safety and efficacy. The short in-vivo half-life of approximately 2.5